The purpose of our study was to evaluate the transduction profiles of herpes simplex virus type 1 (HSV-1)-based amplicon vectors following subretinal injection in the rat. Two amplicon vectors were tested, pHy-CMVGFP and pHy-RPEGFP, both carrying the green fluorescent protein (GFP) under the control of the cytomegalovirus (CMV) ubiquitous promoter or the RPE65-specific promoter, respectively. For the two amplicon vectors, the GFP reporter gene was efficiently expressed in retinal pigment epithelial (RPE) cells but not in the adjacent photoreceptors. GFP expression was maximum as early as 2 days postadministration but decreased over time to become almost undetectable at 6 weeks postinjection. Supertransduction with a second amplicon vector, pHSVlac, reactivated expression of GFP in approximately 10% of the cells initially transduced at 2 days postinjection of pHy-CMVGFP or pHy-RPEGFP. Reactivation of transgene expression was transient, no GFP signal was detected 8 days after pHSVlac injection. In conclusion, HSV-1 amplicon vectors allow rapid and efficient, but transient, gene transfer in RPE cells following subretinal injection.
The retina has several advantages as a target organ for gene transfer. It is easily accessible and allows local application of vectors. Furthermore, transgene expression within the retina and effect of gene transfer may be monitored by a variety of noninvasive examinations.
Several viral vectors based on adenovirus, adenoassociated virus (AAV), or lentivirus were tested for retina transduction. [1] [2] [3] Until now, efficient long-term gene transfer was documented only for the AAV and lentiviral-based vectors.
Following subretinal delivery, rAAV-2 vectors transduce RPE and photoreceptor cells. [4] [5] [6] We and others have studied rAAV chimeric serotypes in which the vector gene sequence is flanked by AAV-2 ITRs, but encapsidated in an AAV-1, -2, -3, -4 or -5 shell generating rAAV-2/1, -2/2, -2/3, -2/4 and -2/5, respectively. In the mouse, subretinal injection of rAAV-2/1gfp showed early onset of GFP expression (3-4 days) with transgene expression restricted to the RPE. In contrast, onset of transgene expression occured at 2-4 weeks for rAAV-2/2 and rAAV-2/5 with both vectors transducing RPE and photoreceptors cells. 7 Subretinal injection of rAAV-2/1, -2/2, -2/3, -2/4 and -2/5 in rats resulted in a hierarchy in the levels of transgene expression, with rAAV-2/4 and -2/5 demonstrating highest efficiency. 8 Further studies with these two vectors have confirmed that rAAV-2/5 transduced both RPE and photoreceptor cells in rat and dog models (the photoreceptors were more efficiently transduced than when rAAV-2/2 was used). rAAV-2/4 allowed exclusive and stable transduction of RPE cells in rodent, canine and non-human primate models. 9 Stable gene transfer into the retina using lentiviral vectors was also reported. Early studies demonstrated conflicting results when determining the tropism of HIV vectors pseudotyped with vesicular stomatitis virus G glycoprotein (VSV-G). Subretinal injection in rats and mice led to the transduction of both photoreceptor cells and RPE. 7, 10, 11 In contrast, Brainbridge et al 3 demonstrated that the transduction was restricted to the RPE in mice. These discrepancies were elucidated recently when it was suggested that the tropism of this vector depends on the age of the animals. 12 In young mice, HIV vectors transduced both RPE and photoreceptors while in older animals, only RPE cells were transduced. Similarly, simian immunodeficiency virus (SIV)-based vectors pseudotyped with VSV-G, influenza A virus hemagglutinin (HA), Mokola virus G protein (MK-G), amphotropic murine leukemia virus envelope (4070A-Env) or lymphocytic choriomeningitis virus G protein (LCMV-G) stably transduced only the RPE cells after subretinal injection in adult rats. 13 There are two types of herpes simplex virus type 1 (HSV-1) vector systems for gene transfer, termed amplicon and recombinant virus. While recombinant HSV-1 vectors have been evaluated for gene transfer into the eye in several studies, [14] [15] [16] [17] 19, 20 or replication-competent, packaging-defective HSV-1 genomes cloned as either a set of cosmids 21 or a bacterial artificial chromosome. [22] [23] [24] [25] As the HSV-1 ori and pac signals are smaller than 1 kb, amplicons have the capacity to accommodate more than 150 kb of foreign DNA, the size of the HSV-1 genome.
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Helper virus-free HSV-1 amplicons have been demonstrated to transfer a wide range of transgenes with high efficiency and low toxicity into many different cells both in culture and in vivo. 27 The major drawback of HSV-1 amplicons is that transgene expression is generally transient. Stability of transgene expression was markedly improved by flanking the transgene cassette with AAV inverted terminal repeats (ITR). [28] [29] [30] The additional inclusion of the AAV rep gene further improved transgene stability due to site-specific integration of the ITR-flanked transgene sequences into the AAVS1 site on human chromosome 19, mediated by the genetic elements from AAV; however, the inclusion of the AAV rep gene drastically reduced the titers of these HSV-1/ AAV hybrid. 30, 31 The present study was designed to evaluate the tropism and the transduction profiles of HSV-1-based amplicon vectors delivered into the subretinal space of rat.
The potential of HSV-1-based amplicon vectors for gene transfer to the retina was assessed with two different vectors expressing GFP from either the cytomegalovirus (CMV) immediate-early (IE) enhancer/ promoter or the retinal pigment epithelial cell-specific RPE65 promoter (Figure 1a and b). In both vectors, the GFP cassette is flanked by AAV ITRs, which do not mediate genomic integration in the absence of AAV rep gene but, nevertheless, have been reported to increase the stability of transgene expression from HSV-1 amplicons. 28 Vector stocks were prepared by using a helper virus-free packaging system to limit vector-associated toxicity. 22, 23 Wistar rats used for this study were handled in accordance with the ARVO Statement for the use of animals in ophthalmic and vision research. pHy-CMVGFP vector (4 Â 10 6 transducing units (TU)/ml corresponding to 8 Â 10 3 TU/injection) was subretinally injected into eight rats. For six animals, retinal images showed efficient transgene expression within the detached portion of the retina as early as 24 h postinjection. GFP signal was maximal at 2 days postinjection but was progressively lost thereafter. No GFP signal could be detected at 6 weeks postinjection (Figure 2a ). Before GFP signal extinction occurred, fluorescence fundus photography of subretinally injected eyes strongly suggested that RPE cells were expressing the transgene. To further characterize the transduced cells within the retina, two animals were killed at 2 days postinjection and the pHy-CMVGFP-injected eyes were enucleated. Retina flatmounts were made and the sclera/choroid/RPE layer was separated from the neuroretina ( Figure 3 ). By examination under a fluorescence inverted microscope, GFP signal was only observed on the sclera/choroid/ RPE layer and showed that RPE cells were efficiently transduced (Figure 3a and b). No signal was detected in the neuroretina layer (Figure 3c ).
To examine if the loss of GFP signal was associated with a loss of RPE cells, two rats were killed at 10 days postinjection and retinal flatmounts were made. As observed on the sclera/choroid/RPE layer, all the RPE cells were intact but the number of RPE cells expressing GFP dramatically dropped between day 2 and 10 p.i. (Figure 3d and e). No RPE destruction or lymphocytes infiltrates were observed. This result suggested that the decrease of GFP expressing cells is likely due to a loss of transgene expression and is not associated with RPE destruction.
HSV-1 amplicon-mediated gene transfer was very efficient. Strong GFP signal was observed with HSV-1 at a titer of 4 Â 10 6 TU/ml, as opposed to rAAV or lentiviral vectors carrying the same cassette of expression, for which transgene expression could not be detected at a titer below 10 8 TU/ml. The HSV-1 amplicon demonstrated a very early onset of transgene expression at 24 h with the maximum level of GFP expression at 48 h postinjection. This onset of expression is more rapid than . 30 The transgene cassette is flanked by the adeno-associated virus (AAV) inverted terminal repeats (ITR). 29 (b) pHy-RPEGFP was constructed by replacing the CMV p/e in pHy-CMVGFP with the RPE65 promoter. Briefly, pSSV9pHRPE65(long)GFP was digested with SpeI, and the 1.43 kb fragment, which contains the RPE65 promoter, was isolated and inserted between the SpeI and NheI sites of pHy-CMVGFP. (c) pHSVlac 38 contains the Escherichia coli lacZ gene under transcriptional control of the HSV-1 IE 4/5 promoter. All vectors contain the HSV-1 origin of DNA replication (oriS) and the HSV-1 DNA cleavage/packaging signal (pac) to support replication of the amplicon DNA into HSV-1 virions in the presence of helper functions. The genetic elements required for amplicon propagation in E. coli, in particular the origin of DNA replication colE1 and the ampicillin-resistance gene, are not indicated. Vector stocks were prepared by using the helper virus-free packaging system as described previously. 22, 23 Briefly, VERO 2-2 cells 39 were cotransfected with 0.4 mg of amplicon DNA, 2 mg of fHSVDpacD27DKn, and 0.2 mg of pEBHICP27 using LipofectAMINE (GIBCO-BRL, Basel, Switzerland). After 3 days, transfected cells were scraped into the medium, the suspension was sonicated, and cell debris was removed by centrifugation (10 min, 1400 g, 41C). For concentration, vectors were pelleted through 25% sucrose (in phosphate-buffered saline, PBS) and resuspended over night in 300 ml of Hank's balanced salt solution (HBSS). To determine titers of unconcentrated and concentrated vector stocks (transducing units per ml; TU/ml), VERO 2-2 cells were infected and, 24 h later, green fluorescent cells were counted using a fluorescence microscope (pHy-CMVGFP and pHy-RPEGFP) or fixed for 20 min with 4 % paraformaldehyde (in PBS), washed three times with PBS and stained with 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-Gal) at 371C (pHSVlac); b-galactosidase-positive cells were counted using a standard light microscope.
In vivo gene transfer to the rat retina C Fraefel et al with lentiviral and rAAV vectors. In contrast to the lentiviral or rAAV vector-transduced retina, where transgene expression was stable over time, 13, 32 the GFP signal progressively decreased to be undetectable at 6 weeks postinjection with HSV-1 amplicon vector. This transient transgene expression is consistent with that observed in the muscle 31 and in the brain. 21 The exclusive tropism of HSV-1 amplicon vectors for RPE cells in adult rat is similar to the tropism shown by lentiviral (HIV and SIV), rAAV1 and rAAV4 vectors. 3, 13, 32 Similarly to lentiviral, rAAV1 and rAAV4 vectors, intravitreal injections of HSV-1 amplicon vectors in adult rats resulted in no detectable transduction (data not shown).
To examine whether the extinction of GFP signal was related to the shutoff of the ubiquitous CMV promoter, a new amplicon containing the GFP transgene under the control of the RPE65-specific promoter was produced (Figure 1 ). RPE65 protein is required for the conversion of vitamin A to 11-cis-retinal by the RPE and is found exclusively expressed in the RPE. 33 pHy-RPEGFP vector (1 Â 10 6 TU/ml corresponding to 2 Â 10 3 TU/injection) were subretinally injected in eight rats. Similarly to pHy-CMVGFP-injected animals, pHy-RPEGFP rats displayed efficient transgene expression within the detached portion of the retina as early as 24 h postinjection with maximal GFP signal at 2 days postinjection. Following the same pattern of extinction, only few cells expressing Figure 2 Retinal imaging showing GFP expression at different time points after pHy-CMVGFP subretinal injection (a) and following pHSVlac 'superinjection' (b). Subretinal injections were performed by way of a transscleral approach on wild-type wistar rats. Briefly, the sclera and the choroid were punctured; a 33-gauge needle was then inserted in a tangential direction under an operating microscope. Fluorescein was added to the viral solution at 1/1000 final dilution, and 2 ml of the injection mixture was delivered into the subretinal space. GFP protein expression in live rats was monitored by fluorescence retinal imaging by using a Canon UVI retinal camera connected to a digital imaging system (Lhedioph win software). Retinas were examined at daily and weekly intervals following injection. At 6 weeks postinjection, when loss of GFP signal was seen, subretinal injection of pHSVlac was performed in the same area of the retina. Efficient transgene expression was detected as early as 24 h postinjection, was maximal at 48 h, and progessively decreased reaching complete extinction at 6 weeks postinjection. Reactivation of GFP expression, following pHSVlac subretinal injection, was observed in approximately 10% of the cells initially transduced. Figure 3 pHy-CMVGFP tropism following subretinal injection. Retina flatmounts were made on pHy-CMVGFP injected eyes at 2 (a, b and c) and 10 days postinjection (d, e and f), by separating the sclera/choroid/RPE layers (a, b, d and e) from the neuroretina (c and f) and were observed under an inverted fluorescence microscope. Rats were killed and the enucleated eyes were fixed with 4% paraformaldehyde for 40 min at room temperature. After washing in PBS, the eyes were cut through the pars plana, and the anterior segment and the lens were removed. The eye cup was cut peripherally in four sections and flattened. The neuroretina was removed from the sclera/choroid/RPE with fine forceps, and both cell layers were examined by fluorescence microscopy. All these steps were processed consecutively with no delay.
In vivo gene transfer to the rat retina C Fraefel et al GFP were detectable at 6 weeks postinjection (Figure 4a ). Tropism studies performed on two pHy-RPEGFP injected rats at 2 days postinjection also showed exclusive transduction of RPE cells (data not shown). As observed on the sclera/coroid/RPE flatmount at 2 and 10 days p.i. and similarly to pHy-CMVGFP-transduced retinas, the decrease of GFP signal was not associated with RPE destruction (data not shown).
Gene transfer using an HSV-1 amplicon carrying the GFP transgene under the control of the RPE65-specific promoter resulted in the same kinetics of transgene expression as with an amplicon in which GFP transgene was under the control of the CMV promoter. In a rAAV or lentiviral context, both of these promoters allowed stable expression of the transgene. 9, 13 The RPE-specific promoter versus the ubiquitous CMV promoter does not prevent the progressive loss of detectable GFP signal in HSV-1 amplicon-transduced retinas. In contrast to lentiviral vectors, which integrate into the chromosome, the HSV-1 amplicon remains episomal. Therefore, the loss of detectable transgene expression over time can be due either to progressive loss of the recombinant sequence in the cell or to the shutoff of both promoters in the context of the amplicon vector.
To examine if components of the vector particle, such as VP16, can transactivate the promoters as previously observed in the brain, 34 we supertransduced the retina with a different HSV-1 amplicon, pHSVlac (Figure 1c) , which expresses the lacZ gene from the HSV-1 IE 4/5 promoter. Vector stocks (1 Â 10 7 TU/ml corresponding to 2 Â 10 4 TU/injection) were subretinally injected in three pHy-CMVGFP and in three pHy-RPEGFP-transduced eyes at 6 weeks after the initial vector administration at the exact same location in the retina.
At 2 days after pHSVlac delivery, approximately 10% of the initially GFP expressing cells were reactivated in both pHy-CMVGFP-transduced animals ( Figure 2b ) and pHy-RPEGFP-transduced animals ( Figure 4b ). As observed in Figures 2b and 4b , all eyes displayed a yellow pattern on the fundus photography few days following supertransduction. Whether this pattern, which suggest a choroidal inflammation, is a consequence of a repeated vector injection or is due to the higher titer of the second amplicon vector remains unclear. No GFP expression was detected in control animals injected with pHSVlac only (data not shown).
The transduction profiles observed in this study closely resemble previous data obtained with HSV-1 amplicon vectors in other organs. Transgene expression reaches a maximum at 2-4 days after injection, gradually declines over days to weeks, independent of the promoter used. 21, 29, 34, 35 Also, the fact that supertransduction with a second vector results in the recovery of transgene expression in a subset of cells previously transduced, is neither surprising nor unprecedented. Supertransduction with a replication-defective recombinant HSV-1 recovered transgene expression in the rat brain, in approximately 30% of the cells previously transduced with an HSV-1 amplicon. 20, 34 In the absence of any viral gene expression, components of the vector particle, such as VP16, may be responsible for reactivation following supertransduction with the second vector. VP16 is an abundant tegument protein that is introduced into the cell nucleus where it transactivates IE promoters. 36 Initially following transduction, the concentrations of the structural vector components are high; over time these transactivating viral proteins are depleted by degradation and, consequently, the activity of the promoters are reduced or shut down. Supertransduction with the second vector restores the initial intracellular concentrations of structural vector components and transgene expression may be reactivated. The structural vector components may act directly on the promoter or, alternatively, induce cellular responses that could influence transgene expression. The differences in reactivation efficiency between our study and the study by Starr et al 34 is most likely due to the different vectors used for the initial transduction and for the reactivation. While we used an HSV-1 amplicon for the reactivation, which contains all the structural components of HSV-1, including VP16, but no viral genes, Starr et al used replicationdefective mutants of HSV-1, which express some of the viral genes. Moreover, in our study, transgene (GFP) expression from the amplicons is controlled by heterologous promoters (CMV or RPE), while in the Starr et al study, 34 trangene (lacZ) expression from the amplicon Figure 4 Retinal imaging showing GFP expression at different time points after pHy-RPEGFP subretinal injection (a) and following pHSVlac 'superinjection' (b). Subretinal injections and retinal imaging were carried out as described above. Similarly to pHy-CMVGFP, efficient transgene expression was detected as early as 24 h postinjection, was maximal at 48 h, and progessively decreased reaching nearly complete extinction at 6 weeks postinjection. Reactivation of GFP expression, following pHSVlac subretinal injection, was observed 2 days postinjection, in approximately 10% of the cells initially transduced.
In vivo gene transfer to the rat retina C Fraefel et al was controled by the HSV-1 IE4/5 promoter, which is transactivated by VP16 protein and viral gene products delivered by the HSV-1 mutants they used for transactivation. The two studies also differ in the methodology of visualizing transgene expression. While we visualized GFP expression in live animals, Starr and colleagues used paraformaldehyde-fixed sections and cytochemical staining with X-gal. The supertransduction study results suggest that extinction of transgene expression in the retina may be due in part to promoter shutoff in at least 10% of transduced RPE cells. It has been previously demonstrated that in the brain, 37 at 60 days post-tranduction, the majority of the HSV vector DNA (80%) disappeared from transduced nuclei. This mechanism of loss of the vector DNA from the nuclei could, therefore, explain at least some of the 90% loss of expression in the retina.
In conclusion, HSV-1 amplicon vectors allow early onset and efficient gene transfer in RPE cells following subretinal injection. This rapid and transient expression of the transgene may limit its usefulness for gene replacement therapy but may be a real advantage for gene therapy of acute diseases.
